<DOC>
	<DOCNO>NCT02867839</DOCNO>
	<brief_summary>The purpose study evaluate efficacy safety S-1 plus Oxaliplatin versus S-1 adjuvant chemotherapy curative distal gastrectomy patient locally advanced gastric cancer .</brief_summary>
	<brief_title>Adjuvant Chemotherapy With S-1 Plus Oxaliplatin Versus S-1 Alone Locally Advanced Gastric Cancer</brief_title>
	<detailed_description>The study multi-central , control , randomized Phase III trial . The protocol approve Ethics Committee Beijing Cancer Hospital . The primary endpoint 3-year progression-free survival ( PFS ) rate . The secondary endpoint overall survival ( OS ) safety .</detailed_description>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<criteria>sign write informed consent form age ≥ 18 year , ≤69 year ECOG status : 0~2 pathologically confirm gastric cancer stage II IIIA ( AJCC 7th version ) negative peritoneal cytology underwent curative distal gastrectomy D2 lymph node dissection prior antitumor treatment allow , include chemotherapy , radiotherapy , immune therapy target therapy adequate organ function define : Hematologic ANC ≥ 2*109/L , Platelets ≥ 100*109/L , AST ALT ≤ 2.5×ULN , TBIL ≤ 1.5×ULN . enrol clinical trial underwent prior antitumor treatment allergic reaction S1 oxaliplatin abnormal GI tract function female pregnancy lactation , refuse receive Contraception measure chemotherapy situation judge adaptive study investigator</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>69 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Gastric cancer</keyword>
	<keyword>Adjuvant chemotherapy</keyword>
	<keyword>S1</keyword>
	<keyword>Oxaliplatin</keyword>
</DOC>